Clinical Trial

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-02-28; most recent amendment 2026-01-06.
Trial Details
NCT Number NCT05749822
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions Primary Biliary Cholangitis
Enrollment 104 participants
Start Date 2023-02-17
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-08